Grade My Investments
HomeFree Stock Grades › ALMR

Alamar Biosciences, Inc. (ALMR) Stock Grade

ALMR · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.5B
P/E Ratio
Revenue Growth (YoY)
0.0%
Net Margin
-40.2%
Return on Equity
18.8%
Dividend Yield
None

About Alamar Biosciences, Inc.'s fundamentals

Alamar Biosciences is a biotech company with a $1.5B market capitalization that reported a net loss in its latest annual statement, resulting in a -40.2% net margin. The company generated no year-over-year revenue growth, indicating flat sales performance in the most recent period. Despite the losses, Alamar's return on equity stands at 18.8%, suggesting the company is generating positive returns relative to shareholder equity. As a pre-profitability biotech firm, the company does not currently pay a dividend.

Track ALMR free — no credit card required. Live grade + monthly AI report →